-
Loading metrics
Open Access
Peer-reviewed
Research Article
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
-
Dongsheng Yue ,
Contributed equally to this work with: Dongsheng Yue, Hui Li, Juanjuan Che
Affiliations Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China, Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Hui Li ,
Contributed equally to this work with: Dongsheng Yue, Hui Li, Juanjuan Che
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Juanjuan Che ,
Contributed equally to this work with: Dongsheng Yue, Hui Li, Juanjuan Che
Affiliation Department of Oncology, Beijing Friendship Hospital of Capital Medical University, Beijing 100050, China
⨯ -
Yi Zhang,
Affiliation Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
⨯ -
Bhairavi Tolani,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Minli Mo,
Affiliation School of Life Sciences, Tsinghua University, Beijing 10084, China
⨯ -
Hua Zhang,
Affiliation Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
⨯ -
Qingfeng Zheng,
Affiliations Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing 100142, China
⨯ -
Yue Yang,
Affiliation Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing 100142, China
⨯ -
Runfen Cheng,
Affiliation Department of Pathology, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
⨯ -
Joy Q. Jin,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Thomas W. Luh,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Cathryn Yang,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Hsin-Hui K. Tseng,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Etienne Giroux-Leprieur,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Gavitt A. Woodard,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ -
Xishan Hao ,
* E-mail: biao.he@ucsfmedctr.org (BH); yuedongsheng_cg@163.com (XH)
Affiliation Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
⨯ -
Changli Wang,
Affiliation Department of Lung Cancer, Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
⨯ -
David M. Jablons,
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ - [ ... ],
-
Biao He
* E-mail: biao.he@ucsfmedctr.org (BH); yuedongsheng_cg@163.com (XH)
Affiliation Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, United States of America
⨯ - [ view all ]
- [ view less ]
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
- Dongsheng Yue,
- Hui Li,
- Juanjuan Che,
- Yi Zhang,
- Bhairavi Tolani,
- Minli Mo,
- Hua Zhang,
- Qingfeng Zheng,
- Yue Yang,
- Runfen Cheng
- Published: July 1, 2015
- https://doi.org/10.1371/journal.pone.0132134